FAS and gastric cancer: A previous investigation uncovered that RHOA Y42C mutation, a driver mutation that accounts for 10–25% of diffuse-type GC, could develop PD-1 blockade resistance by stimulating PI3K-AKT-mTOR-FAS signaling (Kumagai et al, 2020).